Patent SG-11201809677X-A (SG)
Title: Cd200 mutant and its uses
Inventor: HUXLEY PHILIP
IPC: C12N15/62
Filed: 2017-05-10
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111101011111111111 0111011111011111111011111101111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/194941 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: (74) Agent: GIBSON, Mark et al.; Sagittarius IP, Three Globe- C07K 14/705 (2006.01) A61K 38/17(2006.01) side, Fieldhouse Lane, Marlow Buckinghamshire SL7 1HZ C12N 15/62 (2006.01) (GB). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/GB2017/051303 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 10 May 2017 (10.05.2017) CA, DZ, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (25) Filing Language: English HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (26) Publication Language: English KW, MK, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (30) Priority Data: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 1608197.8 10 May 2016 (10.05.2016) GB SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: DUCENTIS BIOTHERAPEUTICS LTD. [GB/GB]; 9 Blenheim Lane, Freeland, Witney Oxfordshire (84) Designated States (unless otherwise indicated, for every OX29 8AW (GB). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventors: HUXLEY, Philip; c/o Ducentis Biotherapeu-UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, tics Ltd., 9 Blenheim Lane, Freeland, Witney Oxfordshire TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, — OX29 8AW (GB). SHERIDAN, Joseph; c/o Ducentis Bio-EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, therapeutics Ltd., 9 Blenheim Lane, Freeland, Witney Ox- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = fordshire OX29 8AW (GB). HEAL, Jonathan; c/o Ducen- TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, tis Biotherapeutics Ltd., 9 Blenheim Lane, Freeland, Wit-KM, ney Oxfordshire OX29 8AW (GB). ML, MR, NE, SN, TD, TG). = (54) Title: CD200 MUTANT AND ITS USES FIGURE 6 Dose response results comparing the inhibition of PMA stimulated oxidative burst in isolated human neutrophils by wild-type CD200-Fc and K130Y = = , \" voy, * = = — 0 = = s 0 f3 a = = X*j 0 a. a A ril 0 5 E P p , • i = CO; • Il Il 7r CI ' 7r CI ' (57) : The invention relates generally to mutant CD200 proteins which bind with greater affinity to the CD200 receptor than ---- wild IN -type CD200, in particular the invention relates to a mutated CD200 protein comprising a mutation at amino acid residue position ,1 130 and/or 131. This invention also relates to a fusion protein comprising the protein as defined herein fused to a non-CD200 protein 0 encoding portion via an optional linker portion, a pharmaceutical composition comprising ei the protein as defined herein and uses thereof. O [Continued on next page] WO 2017/194941 Al MIDEDIMOMOIDEIROIDEMOMOHEIBIOSHIMOVOIMIE Published: — with international search report (Art. 21(3)) — with amended claims and statement (Art. 19(1)) — with sequence listing part of description (Rule 5.2(a))